A review of open-label renal and bone mineral density safety data
Telemedicine Consult - Dr. Gish
Schedule Telemedicine Consult with Dr. Gish

A review of open-label renal and bone mineral density safety data

A review of open-label renal and bone mineral density safety data in patients who switched from TDF to VEMLIDY at Week 96

Robert Gish, MD, reviews clinical study design and 48-week open-label safety data in patients who switched from TDF to VEMLIDY at Week 96, including the effects on renal laboratory parameters and bone mineral density at Week 144.

Watch Video


Metadata